Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
March 16, 2022 07:00 ET
|
Adagene, Inc.
– ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific – – First SAFEbody candidate to advance into combination clinical trial, building on strong single-agent...
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 17:28 ET
|
Adagene, Inc.
- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform - - SAFEbody®...
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
March 02, 2022 06:00 ET
|
Adagene, Inc.
- Total potential transaction value of $2.5 billion plus royalties - SAN DIEGO and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company...
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 08, 2022 07:00 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
Adagene Announces Board and Management Appointments to Support Pipeline Growth
February 02, 2022 16:05 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today...
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
January 27, 2022 07:00 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
January 19, 2022 07:00 ET
|
Adagene, Inc.
- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- ...
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
January 13, 2022 04:00 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase 1b/2 clinical trial of the...
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates
December 22, 2021 16:05 ET
|
Adagene, Inc.
- Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...
Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™
December 13, 2021 10:23 ET
|
Adagene, Inc.
- Posters presented at the 63rd American Society of Hematology Annual Meeting - SAN DIEGO and SUZHOU, China, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...